1 Introduction
Boron neutron capture therapy (BNCT) is a binary radiotherapy based on the 10B(n, α)7Li capture reaction, which releases two charged particles (i.e., α and 7Li) with high linear energy transfer [1, 2]. The ranges of these particles (α < 10 and 7Li < 5 μm) are smaller than the cell size (~10 μm), and as a result, the energy is deposited only in the tumor cells where the boron-drug accumulates [3–5]. Therefore, in clinical situations, acquiring the precise distribution of 10B is key to predicting the therapeutic effects [6]. However, the blood-boron concentration measurement method used in current clinical trials is limited by its use of universal pharmacokinetics, which cannot accurately describe the three-dimensional distribution of boron drugs in individualized patients during treatment [7, 8].
To address the boron concentration detection problem, a variety of in vivo boron concentration measurement methods have been proposed, and some key technical problems have been studied. Among the in vivo boron concentration measurement methods reported, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are considered to be applicable clinically. The principle of PET is the detection of annihilation photons emitted from a region of interest (ROI). In clinical studies, patients are injected with tumor-targeted drugs labeled with a positron decay nuclide prior to treatment (i.e., 18F-BPA in BNCT). The drugs emit positrons through the decay of radionuclides. The range of positrons is short, and they will quickly annihilate with the surrounding electrons to produce a pair of annihilation photons with the same energy (i.e., 511 keV) and opposite motion directions. Thus, the distribution of annihilation photons is considered as the distribution of tumor-targeted drugs. When the drug distribution is relatively stable after a certain period of injection, a PET scanning device is used to detect and reconstruct the distribution of annihilation photons and thereby obtain the distribution of tumor-targeted drugs in the ROI of the patient. PET scanning can be used to assess whether the patient is suitable for BNCT, and the reconstructed drug distribution can be used in treatment planning. Shimosegawa et al. studied the changes in the concentration of 18F-BPA in normal organs of six healthy volunteers and demonstrated that the changes in the 10B concentrations of the normal organs are both time-dependent and dynamic [9]. These results also illustrate that it is necessary to monitor the boron concentration in normal tissues exposed to irradiation during treatment. Watabe et al. studied a method for estimating the absolute boron concentrations in tissues and tumors using rat xenograft models and determined that an underestimation of the partial volume effect using PET to estimate the boron concentration in the lungs, small intestine, and large intestine will increase the adverse effects [10]. Aihara et al. reported the first clinical case of BNCT for head and neck malignancies using 18F‐BPA PET in Kawasaki Medical School, and the BPA-accumulating capacity of the tumor by 18F‐BPA PET was confirmed prior to BNCT [11]. However, with the current technology, PET imaging can only measure the boron distribution before treatment. Therefore, the therapeutic dose distribution calculated using the boron-drug distribution measured using PET imaging may be different from the dose delivered through BNCT treatment.
As another boron dose monitoring method with significant clinical application potential, the principle of SPECT is to detect the distribution of prompt gamma (PG) rays with an energy of 478 keV, which is different from PET scanning. Approximately 94% of 7Li recoil nuclei produced by the boron neutron capture reaction will release 478 keV PG rays. A SPECT scanning system for detecting this PG ray and reconstructing the primary gamma ray (i.e., prompt gamma rays) source distribution in the ROI of a patient during treatment can be used to estimate the boron dose [12], which is the major component of the total therapeutic dose of BNCT. Theoretically, a method based on SPECT scanning can be used during treatment. To promote the clinical translation of this method, researchers have carried out numerous studies on detectors, instrumentations, and other devices [13]. Semiconductor detectors have attracted significant attention owing to their high stopping power and good energy resolution [14]. Murata et al. focused on the feasibility of using a CdTe detector to detect this PG ray and optimized the design of the detection system to achieve an effective resolution of both the ray and the annihilation photons [13, 15]. Fatemi et al. proposed the use of a CZT detector as a PG detector and carried out a series of experimental feasibility and performance optimization analyses based on the nuclear reactor of the University of Pavia, Italy [12, 16]. In addition to the research on semiconductor detectors, some scholars have carried out studies on the design and performance of SPECT systems based on scintillator detectors, and many design schemes have been proposed [17–19]. In addition to the selection and optimization of detector materials, the optimization of the overall structure of the SPECT system can also improve the detection results because the radiation field of the BNCT environment is composed of neutrons and gamma rays with different energies. Hales et al. proposed a method using BGO as an anti-Compton suppression detector, the results of which indicate that the detection performance was improved [20]. Gong et al. used the Monte Carlo method to analyze the influence of boron concentration in tumors on the reconstruction results using the ML-EM algorithm [21]. BNCT-SPECT has a promising prospect for clinical application, but can only estimate the boron dose during treatment, which means it cannot predict the distribution of boron concentration and the total therapeutic dose.
To more comprehensively use the information of PG rays during BNCT, the boron concentration and dose should be measured simultaneously using PG rays with energies of 478 keV and 2.224 MeV, which are generated through the reaction of 1H(n, γ)2H. Further research on the reaction mechanisms for this method should be conducted to promote the clinical application of this detection method in the future. In this study, a detection method is proposed to detect and reconstruct the three-dimensional distribution of boron concentration, and a detailed theoretical derivation of this detection method is discussed. The influencing factors (i.e., neutron energy, anatomical structure, size, and heterogeneity of the voxel) of the method for clinical conditions are demonstrated using the Monte Carlo method.
2 Material and Methods
2.1 Principles for detecting three-dimensional boron concentration and dose in BNCT
In this study, a detection method for the three-dimensional distribution of boron concentration is proposed based on the reaction mechanism of neutrons captured by 1H and 10B isotopes. The detection method can be expressed through Eq. (1), in which
where
The detailed derivation of the proposed three-dimensional boron concentration detection method used in this study is as follows. As shown in Fig.1, when an epithermal/thermal neutron beam travels through the tissues of interest, neutrons interact with different isotopes in the tissues. Considering the content of different isotopes in the tissues and the neutron capture cross section, with BNCT, incident neutrons mainly interact with 1H and 10B isotopes. These reactions emit PG rays with different energies (i.e., 478 keV and 2.224 MeV).
-202104/1001-8042-32-04-002/alternativeImage/1001-8042-32-04-002-F001.jpg)
To measure the three-dimensional distribution of the boron concentration, we calculated the boron concentration at the voxel level. For a voxel of interest, the distribution of 10B and 1H concentrations can be uniformly distributed. Thus, the production rate of different PG rays in the voxel of interest within the neutron irradiation can be described as follows:
where
For a given voxel, the concentrations of different elements in a voxel can be considered as constants. Thus, the ratio of PG ray production in a voxel can be described as
where K(E) is the ratio of the cross section of neutrons captured by the 10B and 1H isotopes. The cross-section of the reaction between neutrons and elements is only related to the energy of the neutron; thus, the physical quantity K(E) can be considered to be related only to the neutron energy.
For a BNCT epithermal/thermal neutron beam, as shown in Fig. 2, the ratio of neutron cross sections that produce the PG rays with 478 keV and 2.224 MeV is almost a constant value over the epithermal/thermal neutron energy range (i.e., less than 10 keV). In the clinical treatment of BNCT, the neutron beam used is an epithermal/thermal neutron beam. According to the IAEA regulations on neutron beams, it is necessary to ensure that the ratio of epithermal neutrons to fast neutrons in the neutron beam is greater than 20. The influence of fast neutrons was ignored when considering the negligible production of PG rays from fast neutrons.
-202104/1001-8042-32-04-002/alternativeImage/1001-8042-32-04-002-F002.jpg)
With the above assumption, Eq. (5) can be simplified as
Equation (1) can be obtained by adjusting Equation (7). In Eq. (1), K,
In practical applications, the yield distribution of different PG rays in all voxels should be analyzed to obtain the three-dimensional distribution of the 10B concentration in the patient.
2.2 Monte Carlo toolkit and configurations
The Monte Carlo simulation software TOPAS 3.1.2 [29] was used to study the multiparticle transport in this study. TOPAS is a particle therapy research oriented Monte Carlo platform based on Geant4 [30–32]. The physical models used in this research include “G4EMStandardPhysics_option4,” “G4HadronPhysicsQGSP_BIC_ AllHP,” “G4DecayPhysics,” “G4IonBinaryCascadePhysics,” “G4HadronElastic PhysicsHP,” “G4StoppingPhysics,” and “G4EmExtraPhysics.” [33, 34].
The component elements of the tumor and normal tissues set in the simulation in this study were all based on the ICRU report 46 [35]. The neutron energy spectrum simulated in this work was obtained from the Massachusetts Institute of Technology (MIT) reactor neutron source [33, 36]. The number of simulated neutrons used during each simulation was 5 × 108, and the calculations for each data were repeated 10 times to determine the statistics of the results. In the simulations, sensitive detectors and filtering scorers were set to obtain the actual PG ray yield information of each voxel under neutron irradiation. During the simulations, each voxel was set as a sensitive detector to detect the number of PG rays generated in each voxel. In addition, a certain energy divergence is considered when recording the PG rays; that is, the yield of each PG ray recorded is the yield of the PG rays within a certain energy range. For PG rays with an energy of 478 keV, the energy range was set as 477 to 479 keV, and the energy range was set as 2.223 to 2.225 MeV for PG rays with an energy of 2.224 MeV.
In this study, three geometric structures were set during the simulations to analyze the different influencing factors on the accuracy of the measured boron concentration, as shown in Figure 3. When analyzing the influence of different neutron components in the incident neutron beam, the geometric structure set during the simulation is as shown as Figure 3a). The mass concentration of hydrogen for all tumor tissues set in this simulation was 0.107. The radius of the tumor was 0.5 cm, and the distribution of the 1H and 10B B isotope concentrations in the tumor voxel was uniform. The boron concentration in the tumor tissue was increased from 10 to 100 ppm at 10 ppm intervals, and only one small tumor tissue was set during each simulation. Figure 3b) shows the structure set used to analyze the influence of the tumor depth and surrounding tissue on the accuracy of the measured boron concentration. Two tumor layers were designed at different depths in the tissue. Each tumor layer was composed of 10 tumor tissues with different boron concentrations. The radius of the tumor tissue was set as 0.5 cm, and the depths of the two layers were 3.5 and 5.5 cm from the surface, respectively. At the same depth from top to bottom, the 10B concentration in the tumor increased from 10 to 100 ppm at 10 ppm intervals. To consider a heterogeneous situation, a bone tissue with a thickness of 1 cm was placed in front of the first tumor layer and the high boron concentration parts (>50 ppm) of the second tumor layer. Based on the structure of the tumor depth and bone tissue set, the neutron spectrum and fluence rate will be different for each tumor voxel. Figure 3c shows the structure used to analyze the influence of the size and heterogeneity of the tumor voxel on the accuracy of the measured boron concentration. To investigate the effect, a spherical geometry composed of two regions (i.e., inner and outer layers) with different 10B concentrations was set during the simulations. The density of the voxels with different boron concentrations set during this simulation is considered to be unchanged, i.e., 1.04 g/cm3. By adjusting the size of the inner and outer layers, the average 10B concentration of different voxels was 50 ppm, and only one small voxel was set during each simulation.
-202104/1001-8042-32-04-002/alternativeImage/1001-8042-32-04-002-F003.jpg)
3 Results and Discussion
3.1 Influence of neutron energy on the accuracy of the measured boron concentration
In Eq. (1), it can be seen that
Figure 4 shows the relationship between
-202104/1001-8042-32-04-002/alternativeImage/1001-8042-32-04-002-F004.jpg)
Table 1 shows the yields of PG rays corresponding to neutrons with different energies (the values in parentheses are counting errors). Under the simulation setting, the proportion of PG rays generated by fast neutrons was only approximately 0.1% of the total PG yield. The proportion of PG rays generated by high-energy neutrons is less than 0.005% of the total PG yield, and the K corresponding to this energy band is no longer fixed. The results indicate that the PG rays produced by fast neutrons will not affect the three-dimensional boron concentration measurement method proposed in this study, and even within this energy region, K is no longer a fixed value assumed in the theoretical derivation.
0.478 MeV | 2.224 MeV | |||||||
---|---|---|---|---|---|---|---|---|
Thermal (<1 eV) | Epithermal (1 eV–10 keV) | Fast (>10 keV) | High energy (>1 MeV) | Thermal (<1 eV) | Epithermal (1 eV–10 keV) | Fast (>10 keV) | High energy (>1 MeV) | |
10 | 43.878% (0.411%) |
56.006% (0.383%) |
0.116% (0.024%) |
0.006% (0.004%) |
43.473% (0.079%) |
56.425% (0.149%) |
0.102% (0.006%) |
0.001% (0.001%) |
20 | 43.885% (0.275%) |
56.011% (0.142%) |
0.105% (0.011%) |
0.002% (0.002%) |
43.477% (0.104%) |
56.421% (0.117%) |
0.102% (0.004%) |
0.002% (0.001%) |
30 | 43.977% (0.188%) |
55.923% (0.180%) |
0.100% (0.006%) |
0.003% (0.003%) |
43.452% (0.092%) |
56.448% (0.114%) |
0.100% (0.004%) |
0.002% (0.001%) |
40 | 43.827% (0.216%) |
56.068% (0.266%) |
0.106% (0.012%) |
0.002% (0.002%) |
43.451% (0.076%) |
56.449% (0.080%) |
0.100% (0.004%) |
0.002% (0.000%)* |
50 | 44.033% (0.266%) |
55.861% (0.167%) |
0.106% (0.006%) |
0.001% (0.000%) * |
43.380% (0.054%) |
56.518% (0.147%) |
0.102% (0.004%) |
0.002% (0.001%) |
60 | 43.967% (0.151%) |
55.928% (0.209%) |
0.105% (0.006%) |
0.002% (0.001%) |
43.458% (0.064%) |
56.440% (0.106%) |
0.102% (0.003%) |
0.002% (0.001%) |
70 | 44.036% (0.156%) |
55.857% (0.120%) |
0.107% (0.007%) |
0.001% (0.001%) |
43.473% (0.081%) |
56.422% (0.096%) |
0.104% (0.004%) |
0.001% (0.000%)* |
80 | 43.978% (0.156%) |
55.911% (0.225%) |
0.112% (0.010%) |
0.001% (0.001%) |
43.453% (0.074%) |
56.443% (0.065%) |
0.104% (0.003%) |
0.001% (0.000%)* |
90 | 43.909% (0.153%) |
55.984% (0.132%) |
0.107% (0.007%) |
0.001% (0.000%)* |
43.409% (0.142%) |
56.488% (0.092%) |
0.103% (0.005%) |
0.002% (0.000%)* |
100 | 43.905% (0.170%) |
55.992% (0.231%) |
0.103% (0.006%) |
0.001% (0.001%) |
43.453% (0.080%) |
56.445% (0.054%) |
0.102% (0.005%) |
0.001% (0.000%)* |
Table 2 shows the relationships between
Thermal (<1 eV) | Epithermal (1 eV–10 keV) | Fast (>10 keV) | High energy (>1 MeV) | Average | |
---|---|---|---|---|---|
10 | 0.060 (0.059%) |
0.059 (0.040%) |
0.068 (1.737%) |
0.250 (39.741%) |
0.060 (0.010%) |
20 | 0.120 (0.088%) |
0.118 (0.030%) |
0.122 (1.534%) |
0.161 (41.680%) |
0.118 (0.040%) |
30 | 0.179 (0.089%) |
0.176 (0.059%) |
0.176 (1.256%) |
0.355 (40.546%) |
0.177 (0.070%) |
40 | 0.239 (0.166%) |
0.235 (0.152%) |
0.250 (4.040%) |
0.288 (39.613%) |
0.237 (0.125%) |
50 | 0.301 (0.209%) |
0.293 (0.132%) |
0.307 (2.931%) |
0.065 (9.604%) |
0.297 (0.102%) |
60 | 0.359 (0.131%) |
0.352 (0.088%) |
0.366 (1.793%) |
0.394 (63.998%) |
0.355 (0.068%) |
70 | 0.420 (0.178%) |
0.410 (0.101%) |
0.426 (3.433%) |
0.308 (70.518%) |
0.415 (0.109%) |
80 | 0.480 (0.197%) |
0.470 (0.176%) |
0.510 (6.285%) |
0.520 (63.364%) |
0.474 (0.118%) |
90 | 0.539 (0.239%) |
0.528 (0.091%) |
0.553 (5.463%) |
0.270 (9.181%) |
0.533 (0.122%) |
100 | 0.600 (0.248%) |
0.589 (0.242%) |
0.599 (5.189%) |
0.539 (59.030%) |
0.593 (0.114%) |
3.2 Influence of tumor depth and surrounding tissue on the accuracy of the measured boron concentration
In the actual BNCT treatment, the neutrons are scattered when neutrons travel through human tissue, and the energy and flux of neutrons reaching the tumor area will become complicated. The yield of different PG rays and the energy deposited in the tumor voxels by complex neutron beams will be significantly different from the results produced by the ideal neutron beams. Thus, in this section, the influences of the tumor depth and surroundings on the accuracy of the measured boron concentration are analyzed.
Based on the geometric structure shown in Fig. 3b, the effect of tissue structure is studied by comparing the PG ratios produced in different tumor layers, the results of which are shown in Fig. 5. The generation of 2.224 MeV PG is only related to the neutron fluence rate and 1H concentration; therefore, the neutron fluence rate at the middle position is high, and the two ends are low because of the influence of neutron scattering from the
-202104/1001-8042-32-04-002/alternativeImage/1001-8042-32-04-002-F005.jpg)
3.3 Influence of the size and heterogeneity of the voxel on the accuracy of the measured boron concentration
In the above study, the distribution of boron concentration in the tumor tissue is even, and thus the influence of boron concentration distribution was ignored. In this case, the average boron concentration of the tumor tissue was equal to the boron concentration of each tumor voxel. In clinical studies, the distribution of boron drugs in patients shows individual differences, and the absorption capacity of boron drugs is also different inside the patient. These factors lead to a non-uniform distribution of boron drugs in the ROI. In this case, the average boron concentration of tumor tissue is not equal to the boron concentration in each tumor voxel, and the yields of different PG rays are different in different tumor voxels. Thus, the influence of boron distribution in a voxel on the accuracy of boron concentration measurements should be clarified.
Figure 6a shows
-202104/1001-8042-32-04-002/alternativeImage/1001-8042-32-04-002-F006.jpg)
4 Conclusion
In conclusion, a method based on the relationship between
Based on the current technologies of radiation detection and dual-energy CT, the boron concentration measurement method has significant potential for clinical applications. It should be noted that there are many technical challenges to implementing the proposed method in clinical applications. We are currently conducting in-depth research on the clinical implementation of this method and the development of relevant detection devices. Furthermore, the method might not be limited solely to BNCT but might also have the potential to measure the 10B concentration and other types of elements in any related field of application.
Boron analysis and boron imaging in biological materials for boron neutron capture therapy (BNCT)
. Crit. Rev. Oncol. Hematol. 68, 66-90 (2008). doi: 10.1016/j.critrevonc.2008.03.004Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT)
. Appl. Radiat. Isot. 88, 2-11 (2014). doi: 10.1016/j.apradiso.2013.11.109Monte Carlo study of the beam shaping assembly optimization for providing high epithermal neutron flux for BNCT based on D–T neutron generator
. J. Radioanal. Nucl. Chem. 310, 1289-1298 (2016). doi: 10.1007/s10967-016-5001-4Study of neutron production and moderation for Sulfur Neutron Capture Therapy
. Nucl. Sci. Tech. 30, 2 (2019). doi: 10.1007/s41365-018-0529-3Design of moderator for boron neutron capture therapy based on D-D neutron source
. Nucl. Tech. 43, 090303 (2020). doi: 10.11889/j.0253-3219.2020.hjs.43.090303 (in Chinese)One stone kills three birds: novel boron-containing vesicles for potential BNCT, controlled drug release, and diagnostic imaging
. J. Mol. Pharm. 11, 3291-3299 (2014). doi: 10.1021/mp400641uCurrent clinical results of the Tsukuba BNCT trial
. Appl. Radiat. Isot. 61, 1089-1093 (2004). doi: 10.1016/j.apradiso.2004.05.010First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome
. Appl. Radiat. Isot. 61, 1101-1105 (2004). doi: 10.1016/j.apradiso.2004.05.060Assessment of 10 B concentration in boron neutron capture therapy: potential of image-guided therapy using 18FBPA PET
. Ann. Nucl. Med. 30, 749-55 (2016). doi: 10.1007/s12149.016.1121.8Practical calculation method to estimate the absolute boron concentration in tissues using 18F-FBPA PET
. Ann. Nucl. Med. 31, 481-485 (2017). doi: 10.1007/s12149.017.1172.5First clinical case of boron neutron capture therapy for head and neck malignancies using 18F‐BPA PET
. Head Neck J. Sci. Spec. Head Neck. 28, 850-855 (2006). doi: 10.1002/hed.20418Innovative 3D sensitive CdZnTe solid state detector for dose monitoring in Boron Neutron Capture Therapy (BNCT)
. Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 936, 50-51 (2019). doi: 10.1016/j.nima.2018.09.135Characterization measurement of a thick CdTe detector for BNCT-SPECT–Detection efficiency and energy resolution
. Appl. Radiat. Isot. 88, 129-133 (2014). doi: 10.1016/j.apradiso.2014.01.023Encoding methods matching the 16×16 pixel CZT detector of a coded aperture gamma camera
. Nucl. Sci. Tech. 31, 92 (2020). doi: 10.1007/s41365-020-00796-5Development of a thick CdTe detector for BNCT–SPECT
. Appl. Radiat. Isot. 69, 1706-1709 (2011). doi: 10.1016/j.apradiso.2011.05.014Preliminary characterization of a CdZnTe photon detector for BNCT-SPECT
. Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 903, 134-139 (2018). doi: 10.1016/j.nima.2018.06.068Progress in The Development of A Tomographic SPECT System For Online Dosimetry In BNCT
. AIP Conf. Proc. 1265, 415-418 (2010). doi: 10.1063/1.3480218Experimental feasibility studies on a SPECT tomograph for BNCT dosimetry
. Appl. Radiat. Isot. 67, 179-182 (2009). doi: 10.1016/j.apradiso.2009.03.044Design of a scintillator-based prompt gamma camera for boron-neutron capture therapy: Comparison of SrI2 and GAGG using Monte-Carlo simulation
. Nucl. Eng. Technol. 53, 626-636 (2021). doi: 10.1016/j.net.2020.07.010Predicted performance of a PG-SPECT system using CZT primary detectors and secondary Compton-suppression anti-coincidence detectors under near-clinical settings for boron neutron capture therapy
. Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 875, 51-56 (2017). doi: 10.1016/j.nima.2017.09.009A Monte Carlo study of SPECT in boron neutron capture therapy for a heterogeneous human phantom
. Int. J. Radiat. Res. 16, 33-43 (2018). doi: 10.18869/acadpub.ijrr.16.1.33Material separation using dual-energy CT: current and emerging applications
. Radiographics. 36, 1087-1105 (2016). doi: 10.1148/rg.2016150220Theoretical variance analysis of single-and dual-energy computed tomography methods for calculating proton stopping power ratios of biological tissues
. Phys. Med. Biol. 55, 1343-1362 (2010). doi: 10.1088/0031-9155/55/5/006Quantum dots enhanced Cerenkov luminescence imaging
. Nucl. Sci. Tech. 30, 71 (2019). doi: 10.1007/s41365-019-0599-xStrategies for accurate response assessment of radiochromic film using flatbed scanner for beam quality assurance
. Nucl. Sci. Tech. 30, 160 (2019). doi: 10.1007/s41365-019-0685-0Spectrometry analysis based on approximation coefficients and deep belief networks
. Nucl. Sci. Tech. 29, 69 (2018). doi: 10.1007/s41365-018-0402-4JENDL-4.0 benchmarking for fission reactor applications
. J. Nucl. Sci. Technol. 48, 172-187 (2011). doi: 10.1080/18811248.2011.9711692JENDL-4.0: a new library for nuclear science and engineering
. J. Nucl. Sci. Technol. 48, 1-30 (2011). doi: 10.1080/18811248.2011.9711675TOPAS: an innovative proton Monte Carlo platform for research and clinical applications
. Med. Phys. 39, 6818-6837 (2012). doi: 10.1118/1.4758060Geant4 developments and applications
. IEEE Trans. Nucl. Sci. 53, 270-278 (2006). doi: 10.1109/TNS.2006.869826GEANT4—a simulation toolkit
. Nucl. instruments methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 506, 250-303 (2003). doi: 10.1016/S0168-9002(03)01368-8GEANT4 calculations of neutron dose in radiation protection using a homogeneous phantom and a Chinese hybrid male phantom
. Radiat. Prot. Dosimetry. 168, 433-440 (2015). doi: 10.1093/rpd/ncv364Dosimetric impact of respiratory motion during boron neutron capture therapy for lung cancer
. Radiat. Phys. Chem. 168, 108527 (2020). doi: 10.1016/j.radphyschem.2019.108527Assessment of long-term risks of secondary cancer in pediatric patients with brain tumor after boron neutron capture therapy
. J. Radiol. Prot. 39, 838-853 (2019). doi: 10.1088/1361-6498/ab29a3Report 46 Journal of the International Commission on Radiation Units and Measurements NP-NP
(1992).Neutronic design of a fission converter-based epithermal neutron beam for neutron capture therapy
. Nucl. Sci. Eng. 131, 1-22 (1999). doi: 10.13182/NSE99-A2015